Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
← Analysis & Perspectives
MillimanAugust 6, 2026

GLP-1 Drug Spending Surge Forces Payers—Including Medicaid—to Rethink Coverage Strategy

Milliman examines the rapid growth of GLP-1 medication spending (from $13.7B to $71.7B in five years) and lays out considerations for payers on benefit design, utilization management, and total cost of care rather than just unit price. While the analysis spans commercial, Medicare, and Medicaid markets broadly, it has direct relevance for Medicaid MCOs and state programs grappling with obesity drug coverage mandates and cost containment, and links to related Milliman work specifically on Medicaid anti-obesity medication coverage.

Pharmacy · Managed Care

Read the full analysis at Milliman →

This is outside commentary from Milliman, not part of Medicaid Monitor's independently scored news coverage.

Share this

More from Milliman

← Analysis & Perspectives

Get the daily briefing.